Results 171 to 180 of about 32,832 (202)

A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma

Investigational New Drugs, 2021
Background Biliary tract cancers (BTC) are rare, chemo resistant and are associated with a poor prognosis. Preclinical and early clinical work had demonstrated interesting anti-tumor activity from targeting fibroblast growth factor receptor (FGFR) pathway.
Daniel H, Ahn, Pedro Luiz Serrano, Uson Junior, Peter, Masci, Heidi, Kosiorek, Thorvardur R, Halfdanarson, Kabir, Mody, Hani, Babiker, Thomas, DeLeon, Mohamad Bassam, Sonbol, Gregory, Gores, Rory, Smoot, Tanios, Bekaii-Saab, Amit, Mahipal, Aaron, Mansfield, Nguyen H, Tran, Joleen M, Hubbard, Mitesh J, Borad   +16 more
openaire   +2 more sources

FGFR Inhibition: Understanding and Overcoming Resistance

Cancer Discovery, 2023
Summary: Facchinetti and colleagues provide key insights into the evolution of resistance to fibroblast growth factor receptor (FGFR) inhibitors, including the development of kinase domain mutations and activation of the PI3K–AKT signaling axis.
Abhishek Tripathi, Daneng Li, Sumanta K. Pal   +2 more
openaire   +2 more sources

FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung

Development, 1998
ABSTRACT Mammalian lungs begin as an outpocket of the foregut, and depend on multiple stages of branching morphogenesis and alveogenesis to reach their final form. An examination of fgf receptor gene expression indicated that all four receptors (fgfr-1 to fgfr-4) are expressed in postnatal lungs at varying levels.
M, Weinstein, X, Xu, K, Ohyama, C X, Deng   +3 more
openaire   +2 more sources

Epigenetic remodelling upon FGFR inhibition

Nature Cell Biology, 2021
FGFR-altered triple negative breast cancer (TNBC) develops adaptive resistance to FGFR inhibitor therapy. A new study shows that sustained FGFR inhibition causes SWI/SNF complex eviction at YAP-recruited enhancers followed by increased mTORC1 activity. Dual inhibition of YAP or mTORC1 and FGFR has a synergistic effect on tumour growth.
Krystal A. Orlando, Paul A. Wade
openaire   +2 more sources

FGFR Inhibition in Urothelial Carcinoma

European Urology
The 2024 US Food and Drug Administration approval of erdafitinib for the treatment of metastatic urothelial carcinoma (mUC) with FGFR3 alterations ushered in the era of targeted therapy for bladder cancer. In this review, we summarize the effects of FGFR pathway alterations in oncogenesis, clinical data supporting FGFR inhibitors in the management of ...
Roger, Li, Joshua, Linscott, James W F, Catto, Siamak, Daneshmand, Bishoy M, Faltas, Ashish M, Kamat, Joshua J, Meeks, Andrea, Necchi, Benjamin, Pradere, Jeffrey S, Ross, Michiel S, van der Heijden, Bas W G, van Rhijn, Yohann, Loriot   +12 more
openaire   +2 more sources

Conserved intron positions in FGFR genes reflect the modular structure of FGFR and reveal stepwise addition of domains to an already complex ancestral FGFR

Development Genes and Evolution, 2009
We have analyzed the evolution of fibroblast growth factor receptor (FGFR) tyrosine kinase genes throughout a wide range of animal phyla. No evidence for an FGFR gene was found in Porifera, but we tentatively identified an FGFR gene in the placozoan Trichoplax adhaerens.
Nicole, Rebscher, Christina, Deichmann, Stefanie, Sudhop, Jens Holger, Fritzenwanker, Stephen, Green, Monika, Hassel   +5 more
openaire   +2 more sources

Lumpers, splitters, and FGFRs

American Journal of Medical Genetics, 1996
The Rapid Publication paper by Cohen on the mutational basis of craniosynostosis is a thorough review of the recent work of our group and of that of others. However, we are concerned that his analysis of the phenotypic variation of Pfeiffer and Jackson-Weiss syndromes obscures important issues that need to be addressed.
Robin M. Winter, Willie Reardon
openaire   +1 more source

Fibroblast growth factor receptor (FGFR)-4, but not FGFR-3 is expressed in the pregnant ovary

Molecular and Cellular Endocrinology, 1997
The intraovarian mechanisms for follicle recruitment, growth, maturation, and ovulation are not well understood. The data suggest that fibroblast growth factor (FGF)-2 is expressed in granulosa and theca cells of growing and mature follicles and in luteal cells during pregnancy.
E E, Puscheck, Y, Patel, D A, Rappolee
openaire   +2 more sources

FGF and FGFR signaling in chondrodysplasias and craniosynostosis

Journal of Cellular Biochemistry, 2005
AbstractThe first experimental mouse model for FGF2 in bone dysplasia was made serendipitously by overexpression of FGF from a constitutive promoter. The results were not widely accepted, rightfully drew skepticism, and were difficult to publish; because of over 2,000 studies published on FGF‐2 at the time (1993), only a few reported a role of FGF‐2 in
P J, Marie, J D, Coffin, M M, Hurley
openaire   +2 more sources

Acquired resistance to selective FGFR inhibitors in FGFR-altered cholangiocarcinoma

European Journal of Cancer, 2020
L. Goyal, I. Baiev, K. Zhang, S. Dalgai, R.T. Shroff, R.K. Kelley, N. Uboha   +6 more
openaire   +1 more source